氟伏沙明治疗COVID-19的作用机制:历史性综述
本综述回顾氟伏沙明对COVID-19的作用机制,涉及5-羟色胺转运体、sigma-1受体和酸性鞘磷脂酶。文章还讨论母亲COVID-19感染与子代神经精神障碍(如孤独症谱系障碍和精神分裂症)风险的可能联系。
要点
- 氟伏沙明对COVID-19的作用机制涉及5-羟色胺转运体、sigma-1受体和酸性鞘磷脂酶。
- 抗抑郁药用于早期COVID-19可能减少插管或死亡风险。
- 氟伏沙明被认为是轻中度COVID-19患者最具吸引力的抗抑郁药。
核心结论
- 抗抑郁药用于早期COVID-19受试者可能降低插管或死亡风险,氟伏沙明是其中最具吸引力的药物。
研究设计与样本
- 历史性综述,回顾氟伏沙明对COVID-19的作用机制。
主要发现
- 氟伏沙明的作用机制包括5-羟色胺转运体、sigma-1受体和酸性鞘磷脂酶。
- 越来越多的临床数据显示抗抑郁药用于早期COVID-19受试者可能与降低插管或死亡风险相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of prophylactic and therapeutic drugs for persons infected with the virus. Drug repurposing for the COVID-19 pandemic has received particular attention. Increasing clinical data suggest that antidepressant use in early-stage subjects with COVID-19 might be associated with a reduced risk of intubation or death. Among the antidepressants, fluvoxamine is the most attractive drug for mild to moderate subjects with COVID-19. In this article, we review the mechanisms of action (i.e., serotonin transporter, sigma-1 receptor, and acid sphingomyelinase) of fluvoxamine for COVID-19. Furthermore, we discuss a possible link between maternal COVID-19 infection and a risk for neuropsychiatric disorders (i.e., autism spectrum disorder and schizophrenia) in offspring.
引用
- Hashimoto Y, Suzuki T, Hashimoto K, et al. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Mol Psychiatry. 2022. PMID: 34997196. doi:10.1038/s41380-021-01432-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。